Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
Respir Res
; 21(1): 139, 2020 Jun 05.
Article
in En
| MEDLINE
| ID: mdl-32503599
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Quinuclidines
/
Benzyl Alcohols
/
Nebulizers and Vaporizers
/
Chlorobenzenes
/
Pulmonary Disease, Chronic Obstructive
/
Androstadienes
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Risk_factors_studies
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Respir Res
Year:
2020
Document type:
Article
Affiliation country:
Country of publication: